Effects of deep brain stimulation of the subthalamic nucleus on patients with Parkinson's disease: a machine-learning voice analysis.

Introduction: Deep brain stimulation of the subthalamic nucleus (STN-DBS) can exert relevant effects on the voice of patients with Parkinson's disease (PD). In this study, we used artificial intelligence to objectively analyze the voices of PD patients with STN-DBS. Materials and methods: In a cross-sectional study, we enrolled 108 controls and 101 patients with PD. The cohort of PD was divided into two groups: the first group included 50 patients with STN-DBS, and the second group included 51 patients receiving the best medical treatment. The voices were clinically evaluated using the Unified Parkinson's Disease Rating Scale part-III subitem for voice (UPDRS-III-v). We recorded and then analyzed voices using specific machine-learning algorithms. The likelihood ratio (LR) was also calculated as an objective measure for clinical-instrumental correlations. Results: Clinically, voice impairment was greater in STN-DBS patients than in those who received oral treatment. Using machine learning, we objectively and accurately distinguished between the voices of STN-DBS patients and those under oral treatments. We also found significant clinical-instrumental correlations since the greater the LRs, the higher the UPDRS-III-v scores. Discussion: STN-DBS deteriorates speech in patients with PD, as objectively demonstrated by machine-learning voice analysis.

High-Level CNN and Machine Learning Methods for Speaker Recognition.

Speaker Recognition (SR) is a common task in AI-based sound analysis, involving structurally different methodologies such as Deep Learning or "traditional" Machine Learning (ML). In this paper, we compared and explored the two methodologies on the DEMoS dataset consisting of 8869 audio files of 58 speakers in different emotional states. A custom CNN is compared to several pre-trained nets using image inputs of spectrograms and Cepstral-temporal (MFCC) graphs. AML approach based on acoustic feature extraction, selection and multi-class classification by means of a Naïve Bayes model is also considered. Results show how a custom, less deep CNN trained on grayscale spectrogram images obtain the most accurate results, 90.15% on grayscale spectrograms and 83.17% on colored MFCC. AlexNet provides comparable results, reaching 89.28% on spectrograms and 83.43% on MFCC.The Naïve Bayes classifier provides a 87.09% accuracy and a 0.985 average AUC while being faster to train and more interpretable. Feature selection shows how F0, MFCC and voicing-related features are the most characterizing for this SR task. The high amount of training samples and the emotional content of the DEMoS dataset better reflect a real case scenario for speaker recognition, and account for the generalization power of the models.

Artificial Intelligence-Based Voice Assessment of Patients with Parkinson's Disease Off and On Treatment: Machine vs. Deep-Learning Comparison.

Parkinson's Disease (PD) is one of the most common non-curable neurodegenerative diseases. Diagnosis is achieved clinically on the basis of different symptoms with considerable delays from the onset of neurodegenerative processes in the central nervous system. In this study, we investigated early and full-blown PD patients based on the analysis of their voice characteristics with the aid of the most commonly employed machine learning (ML) techniques. A custom dataset was made with hi-fi quality recordings of vocal tasks gathered from Italian healthy control subjects and PD patients, divided into early diagnosed, off-medication patients on the one hand, and mid-advanced patients treated with L-Dopa on the other. Following the current state-of-the-art, several ML pipelines were compared usingdifferent feature selection and classification algorithms, and deep learning was also explored with a custom CNN architecture. Results show how feature-based ML and deep learning achieve comparable results in terms of classification, with KNN, SVM and naïve Bayes classifiers performing similarly, with a slight edge for KNN. Much more evident is the predominance of CFS as the best feature selector. The selected features act as relevant vocal biomarkers capable of differentiating healthy subjects, early untreated PD patients and mid-advanced L-Dopa treated patients.

The Emotion Probe: On the Universality of Cross-Linguistic and Cross-Gender Speech Emotion Recognition via Machine Learning.

Machine Learning (ML) algorithms within a human-computer framework are the leading force in speech emotion recognition (SER). However, few studies explore cross-corpora aspects of SER; this work aims to explore the feasibility and characteristics of a cross-linguistic, cross-gender SER. Three ML classifiers (SVM, Naïve Bayes and MLP) are applied to acoustic features, obtained through a procedure based on Kononenko's discretization and correlation-based feature selection. The system encompasses five emotions (disgust, fear, happiness, anger and sadness), using the Emofilm database, comprised of short clips of English movies and the respective Italian and Spanish dubbed versions, for a total of 1115 annotated utterances. The results see MLP as the most effective classifier, with accuracies higher than 90% for single-language approaches, while the cross-language classifier still yields accuracies higher than 80%. The results show cross-gender tasks to be more difficult than those involving two languages, suggesting greater differences between emotions expressed by male versus female subjects than between different languages. Four feature domains, namely, RASTA, F0, MFCC and spectral energy, are algorithmically assessed as the most effective, refining existing literature and approaches based on standard sets. To our knowledge, this is one of the first studies encompassing cross-gender and cross-linguistic assessments on SER.

Machine Learning-based Voice Assessment for the Detection of Positive and Recovered COVID-19 Patients.

Many virological tests have been implemented during the Coronavirus Disease 2019 (COVID-19) pandemic for diagnostic purposes, but they appear unsuitable for screening purposes. Furthermore, current screening strategies are not accurate enough to effectively curb the spread of the disease. Therefore, the present study was conducted within a controlled clinical environment to determine eventual detectable variations in the voice of COVID-19 patients, recovered and healthy subjects, and also to determine whether machine learning-based voice assessment (MLVA) can accurately discriminate between them, thus potentially serving as a more effective mass-screening tool. Three different subpopulations were consecutively recruited: positive COVID-19 patients, recovered COVID-19 patients and healthy individuals as controls. Positive patients were recruited within 10 days from nasal swab positivity. Recovery from COVID-19 was established clinically, virologically and radiologically. Healthy individuals reported no COVID-19 symptoms and yielded negative results at serological testing. All study participants provided three trials for multiple vocal tasks (sustained vowel phonation, speech, cough). All recordings were initially divided into three different binary classifications with a feature selection, ranking and cross-validated RBF-SVM pipeline. This brough a mean accuracy of 90.24%, a mean sensitivity of 91.15%, a mean specificity of 89.13% and a mean AUC of 0.94 across all tasks and all comparisons, and outlined the sustained vowel as the most effective vocal task for COVID discrimination. Moreover, a three-way classification was carried out on an external test set comprised of 30 subjects, 10 per class, with a mean accuracy of 80% and an accuracy of 100% for the detection of positive subjects. Within this assessment, recovered individuals proved to be the most difficult class to identify, and all the misclassified subjects were declared positive; this might be related to mid and short-term vocal traces of COVID-19, even after the clinical resolution of the infection. In conclusion, MLVA may accurately discriminate between positive COVID-19 patients, recovered COVID-19 patients and healthy individuals. Further studies should test MLVA among larger populations and asymptomatic positive COVID-19 patients to validate this novel screening technology and test its potential application as a potentially more effective surveillance strategy for COVID-19.